Factors affecting survival in patients with Pneumocystis jirovecii infection
Factors Associated With Survival in Patients With a Positive Sample for Pneumocystis Jirovecii at the Strasbourg University Hospital: a Retrospective Study From 2016 to 2018
University Hospital, Strasbourg, France · NCT06173453
This study looks at how different factors affect survival rates in adults with a serious lung infection caused by a fungus called Pneumocystis jirovecii, especially in those with weakened immune systems.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France (other) |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT06173453 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the overall mortality rates at six weeks and three months in patients with a positive respiratory sample for Pneumocystis jirovecii, a fungus that can cause serious infections, particularly in immunocompromised individuals. The study will include adult patients treated at Strasbourg University Hospitals from 2016 to 2018, focusing on both those who are colonized and those who are symptomatic. By analyzing data from these patients, the researchers hope to gain insights into the factors associated with survival in this population.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients with a positive respiratory sample for Pneumocystis jirovecii treated at Strasbourg University Hospitals.
Not a fit: Patients who have expressed opposition to the reuse of their data for scientific research purposes will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve understanding of Pneumocystis jirovecii infections and inform better management strategies for affected patients.
How similar studies have performed: While studies on P. jirovecii-related mortality exist, this approach of including both colonized and symptomatic patients is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * Adult patients with a positive respiratory sample for P. jirovecii cared for in Strasbourg University Hospitals between 01/01/2016 and 31/12/2018. Positive samples are defined as a direct examination finding cysts or trophozoites after staining with May-Grunewald-Giemsa and/or Gomori-Grocott, a positive P. jirovecii PCR on sputum, tracheal aspirates or bronchial fluid -alveolar * Subject not objecting to the reuse of their data for scientific research purposes. Exclusion criteria: - Subject having expressed its opposition to the reuse of its data for scientific research purposes.
Where this trial is running
Strasbourg
- Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France — Strasbourg, France (RECRUITING)
Study contacts
- Study coordinator: François DANION, MD
- Email: Francois.danion@chru-strasbourg.fr
- Phone: 33 3 69 55 15 88
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Pneumocystis Jirovecii Infection, P jirovecii Infection, Pneumocystis Infections, Pneumocystis jirovecii Infection, Pneumocystis jirovecii, Pneumonia, Pneumocystis